Literature DB >> 35673416

The global scientific publications on gut microbiota in type 2 diabetes; a bibliometric, Scientometric, and descriptive analysis.

Hojat Dehghanbanadaki1, Hossein Aazami2,3, Hanieh Sadat Ejtahed1, Ahmad Sohrabi4, Shahrbanoo Keshavarz Azizi Raftar5,6, Samira Tarashi5,6, Ozra Tabatabaei-Malazy7,1, Golnaz Bahramali8, Seyed Davar Siadat5,6, Ensieh Nasli Esfahani9, Farideh Razi9.   

Abstract

Background: Modifying gut dysbiosis has achieved great success in managing type 2 diabetes mellitus (T2DM) and also T2DM affected the gut microbial composition.
Objectives: To determine the research trend of scientific publications on the relationship between gut microbiota and T2DM through a bibliometric and descriptive approach. Method: We included originals and reviews related to both topics of gut microbiota and T2DM through searching in Scopus up to 31 December 2019 and then characterized their bibliometric profiles including the number of publications, citations, institutions, journals, countries, and the collaboration network of authors, countries, terms and keywords. Moreover, we performed a descriptive evaluation of the clinical trials based on their intervention type and its influence on gut dysbiosis.
Results: We achieved 877 articles (436 originals and 441 reviews) according to our inclusion criteria. The annual publications were constantly increased over time and reached 220 publications in 2019. Out of 436 original articles, 231 animal studies and 174 human studies were found. The majority of human studies were clinical trials (n = 77) investigating the influence of drugs (n = 21), regimens (n = 21), pre/pro/symbiotic (n = 19), surgeries (n = 15), or both drug and regimen (n = 1) on gut dysbiosis. Roux-en-Y gastric bypass and metformin were assessed the most in these trials. Obesity side by side T2DM has been assessed in this area of literature based on term and keyword analyses showing their possible similar pathways mediated by gut microbiota.
Conclusion: The exponentially growing documents on gut microbiota and T2DM had been published during the last decade and revealed gut microbiota alteration mediated antidiabetic effect of many interventions. Thus, we suggest other researchers to consider this pathway in efficacy assessment of therapeutic modalities and to find the optimal composition of gut microbiota that guarantees healthy insulin sensitivity. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-021-00920-1. © Springer Nature Switzerland AG 2021.

Entities:  

Keywords:  Bibliometrics; Gut microbiota; Microbiome; Probiotic; Scientometrics; Type 2 diabetes

Year:  2021        PMID: 35673416      PMCID: PMC9167415          DOI: 10.1007/s40200-021-00920-1

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  39 in total

1.  Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.

Authors:  Lulu Sun; Cen Xie; Guang Wang; Yue Wu; Qing Wu; Xuemei Wang; Jia Liu; Yangyang Deng; Jialin Xia; Bo Chen; Songyang Zhang; Chuyu Yun; Guan Lian; Xiujuan Zhang; Heng Zhang; William H Bisson; Jingmin Shi; Xiaoxia Gao; Pupu Ge; Cuihua Liu; Kristopher W Krausz; Robert G Nichols; Jingwei Cai; Bipin Rimal; Andrew D Patterson; Xian Wang; Frank J Gonzalez; Changtao Jiang
Journal:  Nat Med       Date:  2018-11-05       Impact factor: 53.440

2.  Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses.

Authors:  Matthew E Falagas; Eleni I Pitsouni; George A Malietzis; Georgios Pappas
Journal:  FASEB J       Date:  2007-09-20       Impact factor: 5.191

Review 3.  Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release.

Authors:  Izumi Kaji; Shin-ichiro Karaki; Atsukazu Kuwahara
Journal:  Digestion       Date:  2014-01-20       Impact factor: 3.216

Review 4.  Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

5.  Differential Changes in Gut Microbiota After Gastric Bypass and Sleeve Gastrectomy Bariatric Surgery Vary According to Diabetes Remission.

Authors:  Rinki Murphy; Peter Tsai; Mia Jüllig; Amy Liu; Lindsay Plank; Michael Booth
Journal:  Obes Surg       Date:  2017-04       Impact factor: 4.129

6.  Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  D M Nathan; J B Buse; M B Davidson; E Ferrannini; R R Holman; R Sherwin; B Zinman
Journal:  Diabetologia       Date:  2008-10-22       Impact factor: 10.122

7.  Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial.

Authors:  Ralph Peterli; Robert E Steinert; Bettina Woelnerhanssen; Thomas Peters; Caroline Christoffel-Courtin; Markus Gass; Beatrice Kern; Markus von Fluee; Christoph Beglinger
Journal:  Obes Surg       Date:  2012-05       Impact factor: 4.129

8.  Diabetes-associated microbiota in fa/fa rats is modified by Roux-en-Y gastric bypass.

Authors:  Tulika Arora; Florian Seyfried; Neil G Docherty; Valentina Tremaroli; Carel W le Roux; Rosie Perkins; Fredrik Bäckhed
Journal:  ISME J       Date:  2017-05-19       Impact factor: 10.302

9.  Distinct patterns in the gut microbiota after surgical or medical therapy in obese patients.

Authors:  Daniel A Medina; Juan P Pedreros; Dannae Turiel; Nicolas Quezada; Fernando Pimentel; Alex Escalona; Daniel Garrido
Journal:  PeerJ       Date:  2017-06-20       Impact factor: 2.984

Review 10.  Worldwide trends in scientific publications on association of gut microbiota with obesity.

Authors:  Hanieh-Sadat Ejtahed; Ozra Tabatabaei-Malazy; Ahmad-Reza Soroush; Shirin Hasani-Ranjbar; Seyed-Davar Siadat; Jeroen Raes; Bagher Larijani
Journal:  Iran J Basic Med Sci       Date:  2019-01       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.